ข่าวประชาสัมพันธ์ Press Releases ข่าวย้อนหลัง หัวข้อข่าว บลอก

วันพฤหัสบดีที่ ๒๑ มิถุนายน พ.ศ. ๒๕๖๑ ๒๐:๔๘ น.

Versus ข่าวประชาสัมพันธ์ “Versus”

How to Have a Healthy Valentines Day General—๙ ก.พ. ๖๑

Thais are the most enthusiastic gift-givers in the Asia-pacific region on valentine's day, with 79% saying they intend to buy their special someone a present, versus just 10% in Indonesia[1]. This year, Bertolli Thailand, the world's number one olive

Takeda Highlights Favorable Safety Profile of Entyvio(R) (vedolizumab) Through Comparative Real-World Data Versus TNF?-Antagonist Therapy in Ulcerative Colitis and Crohn#s Disease Heathcare—๔ มิ.ย. ๖๑

OSAKA, Japan--4 Jun--PRNewswire-FirstCall/InfoQuest
Takeda demonstrates leadership in GI by featuring new U.S. VICTORY Consortium data among its 24 sponsored Entyvio abstracts presented at the Digestive Disease Week (DDW) 2018 meeting

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced a new analysis of real-world data comparing the safety data of the gut-selective biologic Entyvio(R) (vedolizumab) and tumor necrosis factor-alpha (TNFα)-antagonist therapy. The results showed numerically lower rates of serious infections (SIs) [6.9% vs 10.1%; odds ratio (OR) 0.67, 95% confidence interval (CI) 0.41-1.07] and significantly lower rates of serious adverse events (SAEs) [7.1% vs 13.1%; OR 0.51, 95% CI 0.32-0.81] in patients treated with Entyvio (n=436) compared to TNFα-antagonist therapy (n=436). This analysis of the VICTORY (Vedolizumab Health OuTComes in InflammatORY Bowel Diseases) Consortium evaluated the occurrence of adverse events (AEs) in patients with ulcerative colitis (UC) and Crohn's disease (CD) who received vedolizumab compared with TNFα-antagonist therapy and was presented as an oral presentation at the 2018 Digestive Disease Week(R) (DDW) annual scientific meeting held from June 2-5 in Washington, D.C.

Data from 872 UC and CD patients (n=334 UC, n=538 CD; n=436 Entyvio; 47% mal

World makes great progress on energy access, but ambitious action needed to achieve sustainable Energy—๒๓ ก.พ. ๖๑

Remarkable progress has been made in broadening electricity access globally, however sustained political will and increased public and private finance are urgently needed to provide affordable and clean energy to the 1.2 billion people without access to

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Heathcare—๗ ธ.ค. ๖๐

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus

SPU: รองอธิการบดีด้านกีฬา ม.ศรีปทุม หนึ่งในทีมหัวหน้าคณะนักกีฬาฯ ร่วมรับมอบชุดกีฬา เวอร์ซุส ทั่วไป—๑๕ ส.ค. ๖๐

ดร.โสภิต ภาโนมัย รองอธิการบดี มหาวิทยาลัยศรีปทุม ในฐานะรองหัวหน้าคณะนักกีฬาฯ(ที่2จากซ้าย) พร้อมด้วย รศ.ดร.วิชิต คนึงสุขเกษม หัวหน้าคณะนักกีฬาฯ รับมอบชุดกีฬา "เวอร์ซุส" จากคุณอัครเดช พรนภดล กรรมการผู้จัดการ บริษัท เวอร์ซุส สปอร์ต จำกัด ผู้ผลิตชุดกีฬา

ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Heathcare—๒๖ ก.ค. ๖๐

DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive

Neovii: Long-term Outcomes After Standard Graft-Versus-Host Disease (GvHD) Prophylaxis in Heathcare—๒๖ มิ.ย. ๖๐

- The 8-year follow-up results of a randomized phase 3 multicenter trial in adult patients with hematologic malignancies clearly showed more favorable results in the Grafalon(R) group - Severe GvHD-free and relapse-free survival was 34% in the

Expedia.co.th? travel data reveal that US and UK travelers are progressively coming to SEA, and Lifestyle—๒๓ มิ.ย. ๖๐

Based on the data from Q1 2017 booking window, with June to August 2017 travel period in mind, versus the same period last year, Expedia.co.th® revealed that Asian cities are seeing the highest demand of travellers from the US and UK for this summer

ICIS: Trump Versus Xi Fuels Growing Uncertainty Across Global Petrochemical Supply Energy—๒๑ เม.ย. ๖๐

The Trump administration is struggling to find a consistent policy direction and it is unclear what is going to happen next. Take last week's summit between President Trump and President Xi Jinping of China. Ahead of the meeting came bellicose language

เวอร์ซุส ร่วมส่งต่ออุปกรณ์กีฬาให้แก่น้องๆ เยาวชนในชนบท เพื่อการเล่นกีฬาอย่างมีความสุข ทั่วไป—๑ มี.ค. ๖๐

บริษัท เวอร์ซุส สปอร์ต กรุ๊ป จำกัด ผู้จัดจำหน่ายเครื่องแต่งกายและอุปกรณ์กีฬาฟุตบอล แบรนด์ VERSUS สุดยอดแหล่งรวมอุปกรณ์สำหรับคนรักกีฬาฟุตบอลตัวจริง นำโดย ทรงเดช พรนภดล President/Owner, ประกาศิต โบสุวรรณ ร่วมด้วยหนังสือพิมพ์สยามกีฬา สนามฟุตบอล Crystal

Bangko Sentral ng Pilipinas moves to regulate digital currency business Stcoks—๘ ก.พ. ๖๐

The Bangko Sentral ng Pilipinas (BSP) will regulate digital platforms for virtual currency transactions, requiring such businesses to register with the central bank and install internal controls versus dirty money. Businesses handling conversions from

Hill-Rom Holdings Inc. Recovery Ratings On Senior Secured And Unsecured Debt Stcoks—๒ พ.ย. ๕๙

BOSTON (S&P Global Ratings) Nov. 1, 2016--S&P Global Ratings today revised its recovery ratings on Hill-Rom Holdings Inc.'s issue-level debt after we revised our assumptions around the proportion of EBITDA generated by guarantor versus

DuPont Reports Third-Quarter 2016 Results Stcoks—๒๗ ต.ค. ๕๙

GAAP1 earnings per share totaled $0.01 versus $0.14 in prior year. Operating earnings2 per share increased to $0.34 from $0.13 in prior year. Sales of $4.9 billion increased 1 percent. Volumes grew 3 percent on increased demand primarily in Performance

Liver Cancer Researchers from AP-HP and Singapore Collaborate on a Prospective Meta-Analysis of Two Heathcare—๖ ต.ค. ๕๙

Cancer researchers from Assistance Publique - Hopitaux de Paris (AP-HP) and The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI) announced that they will

Nigeria banks to set naira rate without central bank intervention: Stcoks—๑๘ มิ.ย. ๕๙

Lagos -- Nigeria's commercial banks will set the first exchange rate of the naira versus the dollar when the currency is allowed to float freely after the central bank abandoned its dollar peg, a senior banking source said. On Wednesday, the central bank

Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 Heathcare—๑๔ มิ.ย. ๕๙

Faster-acting insulin aspart improved postprandial glucose (PPG) control in type 1 and type 2 diabetes New phase 3a findings showed that faster-acting insulin aspart demonstrated a statistically significant reduction in HbA1c in type 1 diabetes,

Movie Guide: 6 คลิปมาใหม่ Batman v Superman: Dawn of Justice Entertainment—๒๕ มี.ค. ๕๙

ปล่อย 6 คลิปซับไทย [Day Versus Knight Clip, Don't Believe Everything You Hear Clip, Flight To D.C. Clip, How Many Good Guys Are Left Clip, Stay Down Clip, You Took Something That Doesn't Belong To You Clip] ของภาพยนตร์ซูเปอร์ฮีโร่ Batman v Superman: Dawn

Photo Release: SSI receives recognition plaque Sustainability Report Award General—๑๘ ธ.ค. ๕๘

Mr.Chaiwat Utaiwan, Vice Chairman of Thai Listed Companies Association, handed over Sustainability Report Award 2015, Recognition Category to Mr. Nava Chantanasurakhon, Group Executive Officer - Group Public Affairs of Sahaviriya Steel Industries Plc.

Ryzodeg(R) Delivers Significantly Lower Rates of Hypoglycaemia and Nocturnal Hypoglycaemia in a Heathcare—๒ ธ.ค. ๕๘

New analyses demonstrate that Ryzodeg(R) (insulin degludec/insulin aspart) achieved successful glycaemic control with significantly lower rates of hypoglycaemia (low blood sugar) and nocturnal hypoglycaemia in patients with type 2 diabetes versus BIAsp

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms Heathcare—๙ พ.ย. ๕๘

-- Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab -- Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to

First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Heathcare—๔ พ.ย. ๕๘

Injectable combinations once every 4 or 8 weeks show comparable efficacy versus daily oral combination therapy Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced that Phase IIb data

Dont Fall In Love With Me: Solo Exhibition by Kowit Wattanarach General—๑๔ ต.ค. ๕๘

Koi Art Gallery is proud to present "Don't Fall In Love With Me" art exhibition to be held from October 15 - November 29, 2015. This exhibition showcases the latest artworks of Kowit Wattanarach, who depicts a tale of infatuation versus love. It's all

New Xultophy(R) (IDegLira) Phase 3b Trial Shows Improvements in Patient-Reported Outcomes Versus Heathcare—๑๕ ก.ย. ๕๘

This material is intended for global medical media only. For journalistic assessment and preparation before publication. New findings from the DUAL(TM) V phase 3b clinical trial showed greater improvements in treatment-related satisfaction and

New Data Confirm Tresiba(R) U200 Delivers Significantly Lower Rates of Confirmed Hypoglycaemia Heathcare—๑๕ ก.ย. ๕๘

New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the U200 formulation of Tresiba(R) (insulin degludec) experienced significantly lower rates

KiSara New World vs. Old World Wine Dinner General—๗ ส.ค. ๕๘

At KiSara, innovation in the world of wine goes head to head with tradition at our special New World versus Old World Wine Dinner. Conrad Bangkok, in partnership with Diageo and IWS, present a magnificent six-course menu of our gifted chefs’

New Xultophy(R) (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Heathcare—๘ มิ.ย. ๕๘

PR Newswire prematurely distributed the press release, "Xultophy(R) (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change and Lower Rate of Hypoglycaemia Versus Insulin Glargine.". All media coverage should be